Sponsored by
For the Inventor. By the Inventor. With the Investor.
How Jennifer Aniston’s LolaVie brand grew sales 40% with CTV ads
The DTC beauty category is crowded. To break through, Jennifer Aniston’s brand LolaVie, worked with Roku Ads Manager to easily set up, test, and optimize CTV ad creatives. The campaign helped drive a big lift in sales and customer growth, helping LolaVie break through in the crowded beauty category.
We curate this newsletter based on Patent Strength—a metric of a patent’s strategic value and its legal ability to withstand challenges.
Table of Contents
Breakthroughs - Companies covered:
Solidion, Chesapeake, Cognizant, Datavault, Jade Biosciences, and Akeso
Recommendations
From IDiyas
Want your company featured to 50,000 plus innovation-minded readers? Sponsor an IDiyas article. Please see our newsletter stats. Send us an email to: [email protected] for details.
Newsletter published 3x weekly. Sign up by clicking on the image above.
🛡️Protect Your Invention
Ready to file? Get a fast, free quote from our network of registered practitioners.
Interested in joining our network of registered practitioners?
Please contact us here.
🔋 ENERGY & MANUFACTURING
Solidion’s "Magic Trick" for Battery Factories
🔬 The Tech: A proprietary liquid-to-solid electrolyte conversion platform. It allows lithium-ion factories to produce solid-state batteries by injecting a special liquid that converts into a solid in-cell, removing the need for entirely new assembly lines.
📈 Stock Ticker: NASDAQ: STI
🏋️♂️ Patent Strength: 96
🔗 Source: PR Newswire - April 21, 2026
🚀 The Big Deal: This is the "easy button" for the EV industry. Instead of spending billions on new factories, manufacturers can just "update" their current ones.
🌊 The Domino Effect: If STI scales this conversion tech, then battery production costs plummet, which leads to $25k EVs that don't catch fire.
Chesapeake’s Sulphide Secret Sauce
🔬 The Tech: A proprietary heap oxidation technology designed to enhance the recovery of metals from sulphide ores, which are notoriously stubborn.
📈 Stock Ticker: OTCQX: CHPGF | TSXV: CKG
🏋️♂️ Patent Strength: 92
🔗 Source: Newsfile Corp - April 23, 2026
🚀 The Big Deal: Getting gold out of sulphide ore used to be like trying to get a teenager out of bed. This patent makes the process efficient enough to actually turn a profit on low-grade deposits.
🌊 The Domino Effect: If metal recovery rates increase, then "unmineable" sites become gold mines (literally), leading to a localized supply boom for precious metals.
Sponsored content
Hiring in 8 countries shouldn't require 8 different processes
This guide from Deel breaks down how to build one global hiring system. You’ll learn about assessment frameworks that scale, how to do headcount planning across regions, and even intake processes that work everywhere. As HR pros know, hiring in one country is hard enough. So let this free global hiring guide give you the tools you need to avoid global hiring headaches.
🤖 ARTIFICIAL INTELLIGENCE & DATA
Cognizant’s "Prescriptive" Decision Maker
🔬 The Tech: One of three new patents (U.S. Pat. No. 12,572,810) covering "Prescriptive Decision Systems." Unlike predictive AI that tells you what might happen, this AI tells you exactly what to do about it.
📈 Stock Ticker: NASDAQ: CTSH
🏋️♂️ Patent Strength: 94
🔗 Source: PR Newswire - April 23, 2026
🚀 The Big Deal: Cognizant is moving from "AI as a toy" to "AI as the boss," automating complex business strategy decisions.
🌊 The Domino Effect: If business decisions are automated, then middle management becomes a Slack bot, leading to massive corporate efficiency (and perhaps some very quiet offices).
Datavault’s Blockchain Valuation Engine
🔬 The Tech: U.S. Patent No. 12,596,819. A platform for AI-driven automated data valuation and blockchain-tokenized storage, allowing users to monetize their own data securely.
📈 Stock Ticker: NASDAQ: DVLT
🏋️♂️ Patent Strength: 91
🔗 Source: ACCESS Newswire - April 22, 2026
🚀 The Big Deal: This turns "data is the new oil" into an actual paycheck for the person who owns the data, rather than just the tech giant stealing it.
🌊 The Domino Effect: If individuals can tokenize and sell their data directly, then the traditional ad-revenue model dies, leading to a "pay-to-play" internet where your browsing history pays your rent.
Sponsored content
Do your searches always hit dead ends?
Tired of long paragraphs from your AI chatbot when you just need to make a quick decision?
heywa answers your questions with visually curated stories instead of walls of text.
Ask heywa a question, refine by what you need and tap through.
Decisions just got easier.
🏥 BIOTECH & HEALTHCARE
Jade Biosciences’ Autoimmune Sniper
🔬 The Tech: While centered on recent Nasdaq listing grants, their core IP (JADE101) targets the cytokine "APRIL" to treat IgA nephropathy without nuking the entire immune system.
📈 Stock Ticker: NASDAQ: JBIO
🏋️♂️ Patent Strength: 93
🔗 Source: BioSpace - April 23, 2026
🚀 The Big Deal: Autoimmune treatments are often "sledgehammers." Jade is building a "scalpel" that could revolutionize how we treat kidney diseases.
🌊 The Domino Effect: If JADE101 passes Phase 2/3, then dialysis centers start seeing fewer patients, leading to a massive shift in chronic kidney care markets.
Akeso’s Cancer "Cornerstone"
🔬 The Tech: Patents covering the Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy. It hits two different cancer checkpoints at once, specifically showing a 91.7% 12-month survival rate in pancreatic cancer.
📈 Stock Ticker: HKG: 9926
🏋️♂️ Patent Strength: 97
🔗 Source: BioSpace / PR Newswire - April 21, 2026
🚀 The Big Deal: Pancreatic cancer has been a "death sentence" for decades. Akeso’s bispecific antibody is achieving survival rates that were previously thought impossible.
🌊 The Domino Effect: If these Phase II results hold in Phase III, then Cadonilimab becomes the first-line global standard, leading to a massive re-valuation of Akeso as a "Global Pharma" player.
Recommendations
Consistent invention is less about flashes of inspiration and more about the transition from individual talent to a repeatable, engineered system. This process is exemplified by "Centurions"—the elite 0.18% of inventors with over 100 patents—who operate within specialized corporate infrastructures designed to treat innovation as a form of controlled infrastructure rather than a series of accidents. By prioritizing depth and "negative knowledge," these creators and their companies don't just solve isolated problems; they build the technical boundaries of the future through a disciplined, systematic mastery of repeatable discovery.
From IDiyas
Osteoarthritis (OA) is often dismissed as just "wear and tear," but in the medical and economic world, it is considered a global public health crisis. Its importance stems from the fact that it is the primary driver of physical disability and a massive drain on global economies. Here is a breakdown of why OA is a critical topic in 2026:
Osteoarthritis is the most common joint disorder in the world, affecting over 527 million people.
The financial numbers associated with OA are staggering. By 2026, the global OA drug market alone is expected to reach $11 billion.
OA rarely travels alone. Because it makes movement painful, it leads to a sedentary lifestyle, which triggers a cascade of other "comorbidities":
We are currently in the midst of an "aging boom." As the global population over 60 doubles, the prevalence of OA is skyrocketing.
The Patent Ticker: Because by the time it's on a shelf, the money's already been made.
The Fine Print: The inventors are busy, the investors are greedy, and the patents are rolling in. A patent today doesn’t guarantee a profit tomorrow. IDiyas is a data and information platform, not a financial advisor. While we love tracking innovation, this newsletter is for educational purposes only. Always conduct your own due diligence before making any financial moves.